SkinBioTherapeutics Q&A: life sciences firm shares update
30th March 2022 11:28
Chief executive officer Stuart J Ashman and chief finance officer Doug Quinn of SkinBioTherapeutics (LSE:SBTX)present their interim financial results and answer a range of investor questions. The event, held on 29 March 2022, is brought to you by our friends at Investor Meet Company.
Highlights
Q&A: 41:25
About the company
SkinBioTherapeutics is a life science company focused on skin health. It is focused on the development of technology to protect, manage and restore skin-utilising proteins found in the human microbiota. It is targeting three specific skin healthcare sectors; cosmetics, infection control, and eczema. The company has one reportable segment, namely the research and development of the SkinBiotix technology.
These articles are provided for information purposes only. Occasionally, an opinion about whether to buy or sell a specific investment may be provided by third parties. The content is not intended to be a personal recommendation to buy or sell any financial instrument or product, or to adopt any investment strategy as it is not provided based on an assessment of your investing knowledge and experience, your financial situation or your investment objectives. The value of your investments, and the income derived from them, may go down as well as up. You may not get back all the money that you invest. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment adviser.
Full performance can be found on the company or index summary page on the interactive investor website. Simply click on the company's or index name highlighted in the article.